Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Agitated Behavior Clear all
Completed Phase 3 Interventional

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510
View directory record Official record
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 10:30 AM EDT
Not yet recruiting Phase 3 Interventional

Phenobarbital for Agitated Delirium

NCT07548489
View directory record Official record
Conditions
Agitated Delirium, Delirium Confusional State, Delirium in the Intensive Care Unit, Hyperactive Delirium
Interventions
Phenobarbital, Conventional therapy group
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 10:30 AM EDT
Withdrawn Phase 4 Interventional

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318
View directory record Official record
Conditions
Psychosis, Agitation, Delirium
Interventions
ziprasidone, Standard therapy
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 1 Interventional

Memesto Wearable Device for Persons With Dementia

NCT05153161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memesto
Device
Lead sponsor
Edgewater Safety Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT03393520
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
93
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 24, 2026, 10:30 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Beyond Listening: A Music-based Intervention

NCT04840173
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Depressive Symptoms
Interventions
Music
Behavioral
Lead sponsor
MJHS Institute for Innovation in Palliative Care
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 24, 2026, 10:30 AM EDT
Terminated Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

NCT05665088
View directory record Official record
Conditions
Agitation, Dementia
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
65 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Los Alamitos, California • Daytona Beach, Florida • Maitland, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Not applicable Interventional

Music Intervention for Agitation Reduction in the Pediatric Intensive Care Unit

NCT03453814
View directory record Official record
Conditions
Critical Illness
Interventions
Music Therapy
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
5 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 24, 2026, 10:30 AM EDT
Terminated Phase 2 Interventional Results available

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

NCT01766336
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Group 1 ELND005, Group 2 ELND005
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years to 95 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

NCT00095719
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Aripiprazole, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 95 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
14
States / cities
Santa Ana, California • Hamden, Connecticut • Hialeah, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 24, 2026, 10:30 AM EDT
Not yet recruiting Phase 2 Interventional

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

NCT07328529
View directory record Official record
Conditions
Aggressive Behavior in Fragile X Syndome
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 2 Interventional

Pain Management and Behavioral Outcomes in Patients With Dementia

NCT00012857
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Pain, Behavior, Agitation
Interventions
acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Valproate in Dementia (VALID)

NCT00071721
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Valproate, Placebo
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
55 Years to 90 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
46
States / cities
Sun City, Arizona • Tucson, Arizona • Irvine, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Oct 24, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Objective Assessment of Behavioral Associations of Patients With Dementia

NCT02617056
View directory record Official record
Conditions
Dementia, Psychomotor Agitation
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 24, 2026, 10:30 AM EDT
Terminated Phase 2 Interventional

INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD

NCT05163717
View directory record Official record
Conditions
Agitation in Adolescents and Young Adults With ASD
Interventions
INP105, Placebo
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Portland, Maine • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 24, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mindful Melody: Feasibility of Implementing Music Listening on an Inpatient Psychiatric Unit and Its Relation to the Use of As Needed Medications for Acute Agitation

NCT04514432
View directory record Official record
Conditions
Agitated; State, Acute Reaction to Stress, Agitation,Psychomotor
Interventions
Music
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 4 Interventional

Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP)

NCT00043849
View directory record Official record
Conditions
Dementia, Parkinson Disease
Interventions
Quetiapine
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Validating the Use of a Subjectively Reported Sleep Vital Sign

NCT03018912
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA), Insomnia, Restless Leg Syndrome (RLS), Hypersomnia Type; Sleep Disorder, Shift Work Sleep Disorders
Interventions
Sleep VS
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fontana, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Not applicable Interventional

CATIE-Alzheimer's Disease Trial

NCT00015548
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Olanzapine, Quetiapine, Risperidone, Citalopram
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
34
States / cities
Tuscaloosa, Alabama • Irvine, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2015 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Phase 3 Interventional

An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's Disease

NCT00097916
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
9
States / cities
San Francisco, California • Westminster, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2012 · Synced Oct 24, 2026, 10:30 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Delirium Recall in Advanced Cancer Patients

NCT00493714
View directory record Official record
Conditions
Advanced Cancer, Delirium
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Not applicable Interventional

Reiki Intervention for Seriously Ill Elders Intensive Care Unit (RISE-ICU)

NCT03685760
View directory record Official record
Conditions
Mechanical Ventilation Complication, Complementary Health Approach
Interventions
Reiki therapy, Sham Reiki
Other
Lead sponsor
Ohio State University
Other
Eligibility
55 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 10:30 AM EDT
Completed No phase listed Observational

Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia

NCT01856010
View directory record Official record
Conditions
Dementia, Aggression, Agitation
Interventions
ECT treatment, Standard Care (Non-ECT group)
Other
Lead sponsor
Pine Rest Christian Mental Health Services
Other
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 24, 2026, 10:30 AM EDT
Completed Not applicable Interventional

Specific Interventions for Agitation in Alzheimer's Disease

NCT00018291
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Risperidone, Gabapentin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 24, 2026, 10:30 AM EDT